News & Updates

Show Multimedia Only

Metformin lowers HCC risk after antiviral therapy in diabetic patients with hepatitis C

11 Feb 2023

Treatment with metformin results in a significant reduction in hepatocellular carcinoma (HCC) incidence following successful antiviral therapy in individuals with diabetes mellitus and chronic hepatitis C (CHC), a recent study has shown.

11 Feb 2023

Isolated anti-HBc positivity ups liver-related death risk

06 Feb 2023

Isolated hepatitis B core antibody (anti-HBc) positivity appears to increase the risk of liver-related and liver cancer mortality, particularly when accompanied by a high fibrosis score, according to a study of Korean adults.

06 Feb 2023

Saroglitazar may lower cardiovascular risk in NAFLD

03 Feb 2023

Treatment with the dual PPAR α/γ agonist saroglitazar helps improve the serum atherogenic lipoprotein profile in patients with nonalcoholic fatty liver disease (NAFLD), regardless of comorbid conditions and statin use, as shown in a study.

03 Feb 2023

Immune checkpoint inhibitors carry some risk of hepatotoxicity

25 Jan 2023

The use of immune checkpoint inhibitors (ICIs) for the treatment of various cancers appears to have hepatotoxic effects, the risk of which is greater with ICI combination therapy than with monotherapy, as reported in a recent study.

25 Jan 2023

Objective response to systemic therapy linked to overall survival in unresectable HCC

23 Jan 2023 by

Objective response to first-line systemic therapy with lenvatinib or sorafenib independently predicts overall survival (OS) in individuals with unresectable hepatocellular carcinoma (HCC), as shown by the subanalysis of the REFLECT study.

23 Jan 2023

Idiopathic/local factor NC-SVT ups risk of recurrent thrombosis

19 Jan 2023

The risk of overall recurrent thrombosis (RT) is greater among individuals with idiopathic/local factor-related noncirrhotic splanchnic vein thrombosis (NC-SVT), reveals a study. Moreover, splanchnic RT can appear without symptoms and requires screening to be detected.

19 Jan 2023

START-FIT: TACE + RT + avelumab promising as conversion therapy for locally advanced unresectable HCC

18 Jan 2023 by

START-FIT, a prospective, single-arm, phase II trial, has found sequential transarterial chemoembolization (TACE) and stereotactic body radiotherapy (SBRT) followed by anti–PD-L1 treatment with avelumab to be a promising strategy for making patients with locally advanced unresectable hepatocellular carcinoma (HCC) amenable to curative treatment.

18 Jan 2023

Elevated homocysteine level tied to higher NAFLD risk

14 Jan 2023

Circulating homocysteine and folate concentrations appear to play a significant role in the development of nonalcoholic fatty liver disease (NAFLD), a study has shown.

14 Jan 2023

NAFLD screening a cost-effective approach among T2DM patients in SG

12 Jan 2023 by

Nonalcoholic fatty liver disease (NAFLD) screening strategies, particularly vibration-controlled transient elastography (VCTE) and fibrosis-4 (FIB-4), are a cost-effective approach to reduce disease burden among type 2 diabetes mellitus (T2DM) patients in Singapore, according to a study.

12 Jan 2023

Corticosteroid poses no excess mortality risk in drug-induced liver injury

09 Jan 2023

Treatment with corticosteroid in patients with drug-induced liver injury (DILI) does not appear to contribute to increased risk of death but rather helps normalize liver enzymes, as shown in a study.